Vyome Holdings (HIND) EBITDA Margin (2015 - 2026)
Vyome Holdings (HIND) posted EBITDA Margin of 3200.02% for Q2 2026, up 10.53% on a QoQ basis from 3576.78% in Q1 2026, and down 255105.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Vyome Holdings (HIND) EBITDA Margin (2015 - 2026) Analysis & Trends
Vyome Holdings has reported EBITDA Margin for 12 years, with the latest figure at 3200.02% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 255105.0% year-over-year to 3200.02% in Q2 2026; TTM through Jun 2026 was 9190.2%, a 892145.0% decrease from a year earlier, with the FY2025 full-year figure at 3269.35%, down 287769.0% from the prior year.
- EBITDA Margin was 3200.02% for Q2 2026 at Vyome Holdings, up from 3576.78% in the prior quarter.
- The five-year high for EBITDA Margin was 95.61% in Q4 2023, with the low at 24761.92% in Q3 2025.
- Average EBITDA Margin over 5 years is 2182.75%, with a median of 332.46% recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin soared 44114 bps in 2023, then slumped 2442950 bps in 2025.
- Over 5 years, EBITDA Margin stood at 536.75% in 2022, then surged by 82 bps to 95.61% in 2023, then tumbled by 336 bps to 416.76% in 2024, then tumbled by 790 bps to 3707.35% in 2025, then advanced by 14 bps to 3200.02% in 2026.
- The last three EBITDA Margin figures came in at 3200.02% (Q2 2026), 3576.78% (Q1 2026), and 3707.35% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | -3,200.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,200.02% |
| Mar 31, 2026 | -3,576.78% |
| Dec 31, 2025 | -3,707.35% |
| Sep 30, 2025 | -24,761.92% |
| Jun 30, 2025 | -648.98% |
| Mar 31, 2025 | -100.21% |
| Dec 31, 2024 | -416.76% |
| Sep 30, 2024 | -332.42% |
| Jun 30, 2024 | -104.53% |
| Mar 31, 2024 | -113.68% |
| Dec 31, 2023 | -95.61% |
| Sep 30, 2023 | -180.05% |
| Jun 30, 2023 | -176.40% |
| Mar 31, 2023 | -246.22% |
| Dec 31, 2022 | -536.75% |
| Sep 30, 2022 | -439.64% |
| Jun 30, 2022 | -319.64% |
| Mar 31, 2022 | -332.50% |
| Sep 30, 2021 | -388.86% |
| Jun 30, 2021 | -104.53% |